August 8, 2014

Genomatica enters bio-polyamides market

So far, Genomatica's business model seems to be doing pretty well as the company tries to stay out of burning cash through manufacturing, letting its partners from the chemical industry do the commercial production and marketing, and Genomatica instead focuses on R&D of various fermentation-based chemicals for its technology licensing portfolio.

The company announced this week that it has entered the bio-based nylon intermediates market focusing on hexamethylenediamine (HMDA), caprolactam, and adipic acid.  Genomatica is developing complete process technologies for the bio-based production of these intermediates, which it will then license to major firms in the nylon value chain.

More on this post...
Post a Comment